Stockreport

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate Inc.  (CING) 
PDF KANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PT [Read more]